However, precise tumour grading is crucial for improved patient surveillance and treatment, which was emphasised by results from the recently published INDIGO trial showing strong clinical efficacy of the IDH1/2 inhibitor vorasidenib in grade 2 IDH-mutant glioma [26]. Here, IDH1 is linked to central nervous system cancer.